Dosage and administration
Enerion ® should be taken following meals. The normal daily dose is 400 mg - 600 mg: 200 mg - 400 mg twice daily (morning and afternoon).
Side effects occur very rarely, with the most common being increased irritability and hyperkinesia (excessive abnormal movements).
Transient agitation and tremor.
Country of Manufacture: France
Availability: in stock
The product is available in different sizes. You can save by choosing a larger size.
Synthesised first by Japanese researchers, Sulbutiamine is a modified thiamine (vitamin B1), that can easily cross blood-brain barrier. In the brain it eventually produces both GABA and acetylcholine, thus affecting adaptability, mood and focus.
Official indications for Sulbutiamine use include:
- Symptomatic treatment of asthenic disorders
- Hypo - and - avitaminoses
- Lingering illnesses
- After surgical interventions
One pack of Enerion® contains 20 or 60 pills, each containing 200 Mg of the active ingredient, which is sufficient for an average of 10 days of supplementation.
Country of Manufacture: France
- Micheau et al (1985) Chronic administration of sulbutiamine improves long term memory formation in mice: possible cholinergic mediation https://www.ncbi.nlm.nih.gov/pubmed/4059305
- Tiev et al (1999) Treatment of chronic postinfectious fatigue: randomized double-blind study of two doses of sulbutiamine (400-600 mg/day) versus placebo https://www.ncbi.nlm.nih.gov/pubmed/10573727
- O Van Reeth (1999) Pharmacologic and therapeutic features of sulbutiamine https://www.ncbi.nlm.nih.gov/pubmed/12973384
- Trovero et al (2000) Evidence for a modulatory effect of sulbutiamine on glutamatergic and dopaminergic cortical transmissions in the rat brain https://www.ncbi.nlm.nih.gov/pubmed/10996447
- Loo et al (2000) Effects of sulbutiamine (Arcalion 200) on psycho-behavioral inhibition in major depressive episodes https://www.ncbi.nlm.nih.gov/pubmed/10858919
- Kiew et al (2002) Effects of Sulbutiamine on Diabetic Polyneuropathy: An Open Randomised Controlled Study in Type 2 Diabetics https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3436103/
- Vein et al (2003) Use of enerion in psychovegetative syndrome with pronounced asthenia https://www.ncbi.nlm.nih.gov/pubmed/14628585
- S Shah (2003) Adjuvant role of vitamin B analogue (sulbutiamine) with anti-infective treatment in infection associated asthenia https://www.ncbi.nlm.nih.gov/pubmed/14710977
- Bizot et al (2005) Chronic treatment with sulbutiamine improves memory in an object recognition task and reduces some amnesic effects of dizocilpine in a spatial delayed-non-match-to-sample task https://www.ncbi.nlm.nih.gov/pubmed/15951087
- Dmitriev et al (2005) Clinical efficacy of the drug enerion in the treatment of patients with psychogenic (functional) erectile dysfunction https://www.ncbi.nlm.nih.gov/pubmed/15776829
- Litvinovich et al (2006) The use of sulbuthiamine (enerion) in the combined therapy of patients with symptomatic focal epilepsy https://www.ncbi.nlm.nih.gov/pubmed/17274400
- Ollat et al (2007) Effects of the association of sulbutiamine with an acetylcholinesterase inhibitor in early stage and moderate Alzheimer disease https://www.ncbi.nlm.nih.gov/pubmed/17675917
- O Levin, L Slizakova (2007) The use of enerion in the treatment of asthenic disorders in patients after mild cranio-cerebral trauma https://www.ncbi.nlm.nih.gov/pubmed/18379496
- T Sobolevsky, G Rodchenkov (2010) Sulbutiamine in sports https://www.ncbi.nlm.nih.gov/pubmed/21204296
- Kang et al (2010) Sulbutiamine counteracts trophic factor deprivation induced apoptotic cell death in transformed retinal ganglion cells https://www.ncbi.nlm.nih.gov/pubmed/20809085
- Kwag et al (2011) Evidence for neuroprotective effect of sulbutiamine against oxygen-glucose deprivation in rat hippocampal CA1 pyramidal neurons https://www.ncbi.nlm.nih.gov/pubmed/22040892
- Farid et al (2016) Stability-Indicating HPTLC Method for Studying Stress Degradation Behavior of Sulbutiamine HCl https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4885403/
- Sevim et al (2017) Sulbutiamine shows promising results in reducing fatigue in patients with multiple sclerosis https://www.ncbi.nlm.nih.gov/pubmed/28755683